1. Home
  2. PRLD vs MDBH Comparison

PRLD vs MDBH Comparison

Compare PRLD & MDBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • MDBH
  • Stock Information
  • Founded
  • PRLD 2016
  • MDBH 1997
  • Country
  • PRLD United States
  • MDBH United States
  • Employees
  • PRLD N/A
  • MDBH 40
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • MDBH
  • Sector
  • PRLD Health Care
  • MDBH
  • Exchange
  • PRLD Nasdaq
  • MDBH Nasdaq
  • Market Cap
  • PRLD 50.1M
  • MDBH 39.3M
  • IPO Year
  • PRLD 2020
  • MDBH 2023
  • Fundamental
  • Price
  • PRLD $0.89
  • MDBH $3.80
  • Analyst Decision
  • PRLD Strong Buy
  • MDBH
  • Analyst Count
  • PRLD 2
  • MDBH 0
  • Target Price
  • PRLD $4.50
  • MDBH N/A
  • AVG Volume (30 Days)
  • PRLD 137.5K
  • MDBH 6.0K
  • Earning Date
  • PRLD 05-06-2025
  • MDBH 05-12-2025
  • Dividend Yield
  • PRLD N/A
  • MDBH N/A
  • EPS Growth
  • PRLD N/A
  • MDBH N/A
  • EPS
  • PRLD N/A
  • MDBH 0.84
  • Revenue
  • PRLD $7,000,000.00
  • MDBH $3,574,131.00
  • Revenue This Year
  • PRLD N/A
  • MDBH N/A
  • Revenue Next Year
  • PRLD N/A
  • MDBH N/A
  • P/E Ratio
  • PRLD N/A
  • MDBH $4.51
  • Revenue Growth
  • PRLD N/A
  • MDBH N/A
  • 52 Week Low
  • PRLD $0.61
  • MDBH $3.61
  • 52 Week High
  • PRLD $6.80
  • MDBH $12.00
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 51.42
  • MDBH 33.72
  • Support Level
  • PRLD $0.77
  • MDBH $4.08
  • Resistance Level
  • PRLD $1.00
  • MDBH $5.06
  • Average True Range (ATR)
  • PRLD 0.11
  • MDBH 0.23
  • MACD
  • PRLD -0.01
  • MDBH -0.04
  • Stochastic Oscillator
  • PRLD 37.18
  • MDBH 13.10

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About MDBH MDB Capital Holdings LLC common

MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.

Share on Social Networks: